Clinical Trial Update: Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating telmisartan for renal perfusion in patients with metabolic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Telmisartan (Telmisartan)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Metabolic Syndrome | Phase 3 | Status: COMPLETED